Johnson & Johnson Innovation – JJDC has re-upped its commitment to the chronic conditions treatment provider having participated in a series C round valuing it at over $1bn post-money.
US-based specialised care provider Thirty Madison received $140m yesterday in a series C round featuring Johnson & Johnson Innovation – JJDC, the corporate venture capital arm of pharmaceutical group Johnson & Johnson.
Growth equity firm HealthQuest Capital led the round, which included Bracket Capital, Greycroft Partners, Northzone, Mousse Partners and Polaris Partners. The deal valued the company at more than $1bn and helped lift its funding to $210m since it was founded in 2017.
Thirty Madison provides treatments for specific…
